重新开始治疗快感缺乏症的药物

IF 101.8 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Nature Reviews. Drug Discovery Pub Date : 2025-04-16 DOI:10.1038/d41573-025-00073-3

Asher Mullard

引用次数: 0

摘要

强生公司（Johnson & Johnson）已停止开发治疗伴有快感缺乏症的抑郁症药物，这对精神疾病“领域”药物的希望是一个打击。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Back to the drawing board for anhedonia drugs

查看原文本刊更多论文

Back to the drawing board for anhedonia drugs

Johnson & Johnson has discontinued development of aticaprant for depression with anhedonia, a blow to hopes for drugs for ‘domains’ of psychiatric disorders. Johnson & Johnson has discontinued development of aticaprant for depression with anhedonia, a blow to hopes for drugs for ‘domains’ of psychiatric disorders.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews. Drug Discovery 医学-生物工程与应用微生物

CiteScore

137.40

自引率

0.30%

发文量

227

期刊介绍： Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. Each issue includes: Highest-quality reviews and perspectives covering a broad scope. News stories investigating the hottest topics in drug discovery. Timely summaries of key primary research papers. Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.